The Effect of the Genistein on the Proliferation of HT1080 and Expression of Membrane Type 1-Matrix Metalloproteinase (MT1-MMP) mRNA.
- Author:
Jin Han KANG
1
;
Hoon MYOUNG
;
Myung Jin KIM
Author Information
1. Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University.
- Publication Type:Original Article ; Clinical Trial
- Keywords:
invasion;
metastasis;
MT1-MMP mRNA;
tyrosine kinase C inhibitor;
genistein
- MeSH:
Basement Membrane;
Beta Particles;
Blotting, Northern;
Cell Line;
Drug Therapy;
Fibrosarcoma;
Genistein*;
Humans;
Intercellular Signaling Peptides and Proteins;
Matrix Metalloproteinase 14;
Matrix Metalloproteinase Inhibitors;
Matrix Metalloproteinases;
Membranes*;
Neoplasm Metastasis;
Oncogenes;
Peptide Hydrolases;
Protein Kinase C;
Protein Kinases;
RNA, Messenger*
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2001;27(4):314-320
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Matrix metalloproteinases have long been viewed as ideal candidates for proteinases that enables tumor cells to permeated basement membrane defenses and invade surrounding tissue. There is growing evidence that the MMPs have an expanded role, as they are important for the creation and maintenance of a microenvironment that facilitates growth and angiogenesis of tumors at primary and metastatic sites. MT-MMPs are not secreted but instead remaining attached to cell surfaces. Although not all of the MT-MMPs are fully characterized, MT-MMPs have important role in localizing and activating secreted MMPs. The MMP genes are transcriptionally responsive to a wide variety of oncogene, growth factors, cytokine, and hormones. Currently, a number of MMP inhibitors are being developed and some have reached clinical trials as anti-metastatic or anti-cancer therapies. MT1-MMP is involved in the activation of proMMP-2. MT1-MMP is significant not only as a tumor marker but as a new target for chemotherapy against cancer. The purpose of this study was to evaluate the effects of protein kinase C inhibitor(genistein) on the proliferation of HT1080 and expression of MT1-MMP mRNA. Human fibrosarcoma cell line HT1080 was cultured and divided 2 groups. The experimental group was treated with 100 microM genistein and incubated 12h, 24h for [3H]-thymidine uptake assay and northern hybridization individually. And the control group was treated with same amount of PBS for the above procedures. [3H]-thymidine incorporation was measured with beta ray detector. And RT-PCR and northern blotting for MT1-MMP mRNA was performed. The results were as follows 1. [3H]-thymidine uptake was reduced in experimental group with statistical significance. 2. MT1-MMP mRNA expression was significantly reduced in experimental group. These results showed that protein kinase C inhibitor (genistein) inhibited proliferation of HT1080 and almost completely blocked transcription of MT1-MMP mRNA. So, it is possible to use the protein kinase inhibitor (genistein) as anti-metastatic and anti-proliferative agent.
